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Background: Proximal complex lesion in superficial femoral artery (SFA) involving femoral bifurcation (FB) remains surgical domain. Indeed 
catheter-intervention has developed, however studies are limited reporting outcome after stenting for this specific territory, focusing on FB with jail 
or not-jail of profunda artery (Profu A).
Methods: From April 2004 to September 2010,104 consecutive, de-novo proximal SFA lesions involving FB treated with self expandable stent were 
derived and retrospectively divided: 60 crossover stentings with jail of Profu-A (jail-group) and 44 just ostial SFA stentings without jail of Profu-A 
(not-jail-group) according to the location of proximal stent edge. FB was defined as peripheral artery portion between distal common femoral artery 
(CFA) within 10mm proximal to orifices of Profu-A and ostia of SFA within 10mm distal to flow-divider. Stenting in CFA proximal to FB was excluded. 
Bifurcation-patency was newly defined as FB without restenosis and any repeat revascularization.
Results: No difference was seen in patient-, lesion- and procedure-characteristics. The rate of TASCIIC/D ( 90% vs. 95%), critical limb ischemia 
(42% vs. 48%), chronic total occlusion (72 % vs. 77 %) were similar. Two of 60 Profu A (3.3%) in jail-group and 1 of 44 Profu-A in not-jail-group 
(2.3%) were occluded after procedure (N.S). Almost all (97.8% vs. 97%: N.S) Profu A after procedure maintained its flow during 12-month. 
In 12-month, either bifurcation patency or primary-patency of SFA was higher in jail-group than in not-jail-group (83.3%vs.56.3%: p<0.01; 
56.2%vs.37.5%: p=0.088, respectively). Predictors of loss of bifurcation-patency were just stenting in ostial SFA (Odds4.39, 95%CI 1.34-
14.4:p<0.05) and stent-size implanted in bifurcation(Odds 0.48, 95% CI 0.25-0.90:p<0.05). In jail-group, 8 loss of bifurcation patency were seen 
during 12 months, but 7 jailed Profu A were patent to be collateral source while SFA was occluded.
Conclusions: Crossover stenting with jail of Profu-A and stent-size implanted in FB were important factors affecting patency of FB despite 
complexity of proximal lesion in SFA involving FB. Fate of jailed Profu A was acceptable at least during 12-month.
